EL7.AI
StocksMediumUpdated×4•Originally published 13 November 2026•Updated 13 November 2026•
4 min read

AstraZeneca targets $1.5 billion in annual savings from restructuring

Key Facts

1AstraZeneca is targeting annual pre-tax benefits at a run rate of $1.5 billion, with one-time restructuring costs of up to $2 billion.
2Total revenue was $16.209 billion in the third quarter of 2026, up 7% at constant exchange rates.
3The pipeline comprised 180 projects, including 116 in Phase II or III and 20 new medicines in late-stage development.
4The company recorded 12 positive Phase III readouts in the first nine months of 2026, with collective peak revenue potential of more than $10 billion.

On October 30, 2026, AstraZeneca announced a restructuring program targeting annual pre-tax benefits at a run rate of $1.5 billion, with one-time costs of up to $2 billion. In a note to investors, the company said the savings would be reinvested mainly in its drug development pipeline. The program puts cost control in service of expanding resources for research and development, as the company reported signs of uneven growth across its therapy areas. AstraZeneca set the end of 2029 as the expected completion date for the program’s activities. The announcement coincided with third-quarter and first-nine-month results, during which the company recorded growth in total revenue.

Total revenue was $16.209 billion in the third quarter of 2026, up 7% at constant exchange rates, and $46.881 billion in the first nine months, up 7% on the same basis. The quarterly figure shows continued expansion, although its growth rate was below the 10% increase recorded in the third quarter of 2025. The company said total revenue growth in the first nine months came alongside double-digit growth in oncology, respiratory and immunology, and rare diseases. By segment, oncology revenue rose 16% and rare disease revenue rose 11% during the period, at constant exchange rates. By contrast, revenue from biopharmaceuticals fell 5%, highlighting differing performance trends across the company’s portfolio.

AstraZeneca attributed some of the pressure on revenue to the loss of exclusivity for Farxiga and Brilinta, as well as volume-based procurement in China. It said these factors offset growth in oncology, respiratory and immunology, and rare diseases during the first nine months. These pressures coincided with total revenue growth of 7% for the period, the same rate recorded in the third quarter. In a further comparison of resource allocation, core research and development expenses rose 3% year on year at constant exchange rates in the third quarter of 2026. Those expenses had increased 14% in the third quarter of 2025, according to company data.

The savings guidance is underpinned by a pipeline that AstraZeneca said comprises 180 projects, including 116 projects for new medicines or major lifecycle management in Phase II or III. The pipeline also includes 20 new medicines in late-stage development. These figures offer a view of the scale of the programs in which the company said savings would be reinvested mainly, with development stages and timelines varying by project. In the first nine months of 2026, the company recorded 12 positive Phase III readouts. AstraZeneca estimated the collective peak revenue potential of these readouts at more than $10 billion; these are estimates of commercial potential, not realized revenue.

Alongside results recorded in the first nine months, Chief Executive Pascal Soriot said readouts expected in 2027 carried revenue potential of more than $20 billion. The company thus distinguished between positive results already reported from Phase III programs and readouts it expects next year. Soriot said AstraZeneca sees itself as “on track to deliver on our 2030 ambition and continue growing through the next decade.” The statement sets a broader timeframe for the company’s strategy, while the restructuring program runs through the end of 2029. AstraZeneca expects reinvestment of the savings to support the pipeline, whose results and clinical milestones are due over the coming period.

AstraZeneca shares were up about 6% by 14:33 GMT on October 30, after rising as much as 7.3% during the day, according to a Reuters report published by MarketScreener. The move came on the day the company announced its third-quarter and first-nine-month results. Commenting on the results, an analyst at Quilter Cheviot said they “should reassure investors after a turbulent period” for the company. Reuters also reported that AstraZeneca is targeting annual revenue of $80 billion by 2030. The company set February 9, 2027, as the date for announcing its full-year and fourth-quarter 2026 results, its next financial reporting date.

Open on chart